Drug class

Antiplatelet and Antithrombotic Drugs (Selected Group 2)

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines. Read more about Antiplatelet and Antithrombotic Drugs (Selected Group 2)

104 drugs in this class 73 manufacturers

Advertisement

Drugs in Antiplatelet and Antithrombotic Drugs (Selected Group 2)

Showing 64–72 of 104 drugs

WARFARIN SODIUM

ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
BRYANT RANCH PR

CILOSTAZOL

INTERMITTENT CLAUDICATION AGENTS · INTERMITTENT CLAUDICATION
NUCARE PHARMACE

DIPYRIDAMOLE

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · THROMBOEMBOLISM DUE TO PROSTHETIC HEART VALVES
OXFORD PHARMACE

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
ATHENEX PHARMAC

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
MEITHEAL PHARMA

WARFARIN SODIUM

ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
APHENA PHARMA S

DOLOBID (diflunisal)

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · RHEUMATOID ARTHRITIS ·+3
INA PHARMACEUTI

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
AVENACY, INC
Filter & compare in the drug finder → Opens the drug finder with Antiplatelet and Antithrombotic Drugs (Selected Group 2) preselected. Add indication or manufacturer filters there.

About Antiplatelet and Antithrombotic Drugs (Selected Group 2).

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines.

Instead, it reflects an administrative, institutional, or formulary-specific grouping rather than an established physiological classification.

Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade.

Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis.